drugset / Trial / NCT01284036

A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects

NCT01284036 ↗

Phase 1 Completed 63 enrolled Ablynx, a Sanofi company
NaSingle-groupTriple-blind

Summary

The purpose of this study is to find the safety and side effects of investigational drug in healthy volunteers. See how quickly investigational drug enters the bloodstream, is distributed in the body, broken down and removed in healthy male and female volunteers. See if your body makes antibodies to this investigational drug (how your immune system responds).

Timeline

Start
2010-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05230905 Unknown — Subcutaneous

Indications

No indication recorded.